Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow MSLE by emailGet an email when MSLE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MSLE, unsubscribe in one click. Privacy
📣 What MSLE Says Is Next
fourth quarter of 2026 · “A Phase 2 clinical study to evaluate the safety, efficacy and tolerability of forazapadin in adults with FSHD is expected to begin in the fourth quarter of 2026.”
Company press release, Sep 24, 2026 · SEC filing
fourth quarter of 2026 · “The funds are expected to support the IND-cleared Phase 2 randomized, double-blind, placebo-controlled proof-of-concept clinical study designed to evaluate the safety, tolerability, pharmacokinetics and potential efficacy of orally administered forazapadin at 60 mg and 120 mg doses in adults aged 18 and older living with FSHD, which we expect to initiate in the fourth quarter of 2026.”
Company press release, Sep 24, 2026 · SEC filing
fourth quarter of 2026 · “The company plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026.”
Company press release, Sep 24, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full MSLE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MSLE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.